Holen Sie sich die Stockscreener-App
28.55
1.84%
-0.535
Handel nachbörslich:
28.55
Schlusskurs vom Vortag:
$29.09
Offen:
$29.28
24-Stunden-Volumen:
446.55K
Relative Volume:
0.22
Marktkapitalisierung:
$542.98M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-19.55
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-2.49%
1M Leistung:
+24.35%
6M Leistung:
+3,460%
1J Leistung:
+2,202%
1-Tages-Spanne:
$27.87
$29.50
1-Wochen-Bereich:
$27.87
$30.45
52-Wochen-Spanne:
$0.432
$37.38
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
28.55 | 553.16M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics’ Strategic Investor Engagement and Pipeline Progress - AInvest
Nektar Therapeutics to Participate in Two Investor Conferences in September - StreetInsider
Biotech Leader Nektar Therapeutics Set for Double Investor Conference Appearances in September 2025 - Stock Titan
Will Nektar Therapeutics outperform the market in YEARProduct Launch & Safe Entry Momentum Tips - khodrobank.com
Published on: 2025-09-03 09:08:30 - Newser
Using fundamentals and technicals on Nektar Therapeutics2025 Volatility Report & Community Shared Stock Ideas - Newser
Nektar Therapeutics stock trend outlook and recovery path2025 AllTime Highs & Reliable Trade Execution Plans - Newser
Will Nektar Therapeutics announce a stock splitQuarterly Risk Review & Reliable Intraday Trade Plans - khodrobank.com
How to manage a losing position in Nektar TherapeuticsQuarterly Trade Report & Low Volatility Stock Recommendations - Newser
Should you wait for a breakout in Nektar TherapeuticsWeekly Profit Recap & Free Safe Entry Trade Signal Reports - Newser
Real time alert setup for Nektar Therapeutics performance2025 Major Catalysts & Growth Focused Entry Reports - Newser
Comparing Nektar Therapeutics in custom built stock radarsWeekly Market Summary & Momentum Based Trading Ideas - Newser
Multi asset correlation models including Nektar TherapeuticsJuly 2025 Volume & Smart Allocation Stock Reports - Newser
Nektar Therapeutics stock outlook for YEARJuly 2025 PreEarnings & Fast Entry High Yield Tips - Newser
Is Nektar Therapeutics stock ready for a breakout2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
What does recent volatility data suggest for Nektar Therapeutics2025 Market WrapUp & Community Trade Idea Sharing - Newser
How to monitor Nektar Therapeutics with trend dashboardsMarket Volume Summary & Fast Exit and Entry Strategy Plans - Newser
Automated trading signals detected on Nektar TherapeuticsPortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Combining machine learning predictions for Nektar TherapeuticsWeekly Risk Report & Weekly Top Gainers Trade List - Newser
Can Nektar Therapeutics recover in the next quarterProfit Target & AI Forecasted Stock Moves - Newser
Will Nektar Therapeutics benefit from macro trendsJuly 2025 Momentum & Expert Curated Trade Setup Alerts - Newser
how to manage a losing position in nektar therapeuticsEarnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
Nektar Therapeutics stock volume spike explained2025 Performance Recap & Community Verified Watchlist Alerts - Newser
How to interpret RSI for Nektar Therapeutics stock2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
Can Nektar Therapeutics continue delivering strong returnsJuly 2025 News Drivers & Weekly Sector Rotation Insights - khodrobank.com
Can momentum traders help lift Nektar TherapeuticsBuy Signal & Community Verified Trade Alerts - Newser
Applying big data sentiment scoring on Nektar Therapeutics2025 Top Gainers & Daily Oversold Bounce Ideas - Newser
What MACD signals say about Nektar TherapeuticsWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Is Nektar Therapeutics stock trending bullishWeekly Trade Summary & Real-Time Stock Price Movement Reports - khodrobank.com
What indicators show strength in Nektar TherapeuticsTrade Risk Report & Daily Price Action Insights - Newser
Why Nektar Therapeutics stock attracts strong analyst attentionCEO Change & Consistent Profit Trade Alerts - Newser
Colorectal Cancer Pipeline Outlook 2025 – Clinical Trials, Medication, Therapies, Companies by DelveInsight - Barchart.com
Measuring Nektar Therapeutics’s beta against major indicesQuarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Candlestick signals on Nektar Therapeutics stock todayJuly 2025 Technicals & Verified Momentum Stock Alerts - Newser
How to build a custom watchlist for Nektar TherapeuticsRate Hike & Weekly Watchlist of Top Performers - Newser
How to use a screener to detect Nektar Therapeutics breakouts2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Using data models to predict Nektar Therapeutics stock movement2025 Big Picture & Real-Time Stock Entry Alerts - Newser
Signal strength of Nektar Therapeutics stock in tech scanners2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):